Clinical Trial Update: Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of bevacizumab and erlotinib for unresectable hepatocellular carcinoma to assess efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hepatocellular Carcinoma, Liver Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-05-06